Patents Assigned to FORENDO PHARMA LTD
-
Publication number: 20220127303Abstract: The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R1 to R4 are as defined in the claims. The invention further relates to their use as inhibitors of 17?-HSD1 and in treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17?-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the afore-mentioned compounds or pharmaceutically acceptable salts thereof.Type: ApplicationFiled: January 11, 2022Publication date: April 28, 2022Applicant: FORENDO PHARMA LTDInventors: Leena HIRVELÄ, Marjo HAKOLA, Tero LINNANEN, Pasi KOSKIMIES, Camilla STJERNSCHANTZ
-
Patent number: 11254703Abstract: The invention relates to compounds of formula (II), and pharmaceutically acceptable salts thereof, wherein R1 to R4 are as defined in the claims. The invention further relates to their use as inhibitors of 17?-HSD1 and in treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17?-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof.Type: GrantFiled: June 5, 2020Date of Patent: February 22, 2022Assignee: FORENDO PHARMA LTDInventors: Leena Hirvelä, Marjo Hakola, Tero Linnanen, Pasi Koskimies, Camilla Stjernschantz
-
Publication number: 20200317718Abstract: The invention relates to compounds of formula (II), and pharmaceutically acceptable salts thereof, wherein R1 to R4 are as defined in the claims. The invention further relates to their use as inhibitors of 17?-HSD1 and in treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17?-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof.Type: ApplicationFiled: June 5, 2020Publication date: October 8, 2020Applicant: FORENDO PHARMA LTDInventors: Leena HIRVELÄ, Marjo HAKOLA, Tero LINNANEN, Pasi KOSKIMIES, Camilla STJERNSCHANTZ
-
Patent number: 10717761Abstract: The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R1 to R4 are as defined in the claims. The invention further relates to their use as inhibitors of 17?-HSD1 and in treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17?-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof.Type: GrantFiled: June 7, 2018Date of Patent: July 21, 2020Assignee: FORENDO PHARMA LTDInventors: Leena Hirvelä, Marjo Hakola, Tero Linnanen, Pasi Koskimies, Camilla Stjernschantz
-
Patent number: 10626140Abstract: The present invention accordingly provides novel compounds of formula (I) wherein R1, R2, R3 and R4 are as defined in the claims. The invention further relates to their in treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17?-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration.Type: GrantFiled: December 22, 2015Date of Patent: April 21, 2020Assignee: Forendo Pharma LTDInventors: Leena Hirvelä, Pasi Koskimies, Risto Lammintausta, Marjo Hakola, Maire Eloranta
-
Patent number: 10413557Abstract: The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R1 to R4 are as defined in the claims. The invention further relates to their use as inhibitors of 17?-HSD1 and in treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17?-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof.Type: GrantFiled: December 22, 2015Date of Patent: September 17, 2019Assignee: FORENDO PHARMA LTD.Inventors: Leena Hirvelä, Pasi Koskimies, Risto Lammintausta, Marjo Hakola, Maire Eloranta
-
Patent number: 10377791Abstract: The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R1 to R6 are as defined in the claims. The invention further relates to their use as inhibitors of 17?-HSD and in treatment or prevention of steroid hormone de-pendent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17?-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof.Type: GrantFiled: June 25, 2014Date of Patent: August 13, 2019Assignee: FORENDO PHARMA LTD.Inventors: Maire Eloranta, Leena Hirvelä, Lauri Kangas, Pasi Koskimies, Risto Lammintausta, Mikko Unkila
-
Publication number: 20180354984Abstract: The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R1 to R4 are as defined in the claims. The invention further relates to their use as inhibitors of 17?-HSD1 and in treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17?-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof.Type: ApplicationFiled: June 7, 2018Publication date: December 13, 2018Applicant: FORENDO PHARMA LTDInventors: Leena HIRVELÄ, Marjo HAKOLA, Tero LINNANEN, Pasi KOSKIMIES, Camilla STJERNSCHANTZ
-
Publication number: 20180265541Abstract: The present invention accordingly provides novel compounds of formula (I) wherein R1, R2, R3 and R4 are as defined in the claims. The invention further relates to their in treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17?-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration.Type: ApplicationFiled: December 22, 2015Publication date: September 20, 2018Applicant: FORENDO PHARMA LTDInventors: Leena HIRVELÄ, Pasi KOSKIMIES, Risto Lammintausta, Marjo HAKOLA, Maire ELORANTA
-
Patent number: 9850272Abstract: The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R2, R3, R4, R7 and R8 are as defined in the claims. The invention further relates to their use as inhibitors of 17?-HSD1 and in treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17?-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof.Type: GrantFiled: June 25, 2014Date of Patent: December 26, 2017Assignee: FORENDO PHARMA LTD.Inventors: Leena Hirvelä, Lauri Kangas, Pasi Koskimies, Risto Lammintausta, Mikko Unkila
-
Publication number: 20170354664Abstract: The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R1 to R4 are as defined in the claims. The invention further relates to their use as inhibitors of 17?-HSD1 and in treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17?-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof.Type: ApplicationFiled: December 22, 2015Publication date: December 14, 2017Applicant: FORENDO PHARMA LTDInventors: Leena HIRVELÄ, Pasi KOSKIMIES, Risto Lammintausta, Marjo HAKOLA, Maire ELORANTA
-
Patent number: 9663549Abstract: The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R2 to R7 are as defined in the claims. The invention further relates to their use as inhibitors of 17?-HSD and in treatment or prevention of steroid hormone de-pendent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17?-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the afore-mentioned compounds or pharmaceutically acceptable salts thereof.Type: GrantFiled: June 25, 2014Date of Patent: May 30, 2017Assignee: FORENDO PHARMA LTD.Inventors: Maire Eloranta, Leena Hirvelä, Lauri Kangas, Pasi Koskimies, Risto Lammintausta, Mikko Unkila
-
Publication number: 20170114090Abstract: The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R1 to R6 are as defined in the claims. The invention further relates to their use as inhibitors of 17?-HSD and in treatment or prevention of steroid hormone de-pendent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17?-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof.Type: ApplicationFiled: June 25, 2014Publication date: April 27, 2017Applicant: FORENDO PHARMA LTDInventors: Maire ELORANTA, Leena HIRVELÄ, Lauri KANGAS, Pasi KOSKIMIES, Risto Lammintausta, Mikko Unkila
-
Publication number: 20170081357Abstract: The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R2 to R7 are as defined in the claims. The invention further relates to their use as inhibitors of 17?-HSD and in treatment or prevention of steroid hormone de-pendent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17?-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the afore-mentioned compounds or pharmaceutically acceptable salts thereof.Type: ApplicationFiled: June 25, 2014Publication date: March 23, 2017Applicant: FORENDO PHARMA LTDInventors: Maire ELORANTA, Leena HIRVELÄ, Lauri KANGAS, Pasi KOSKIMIES, Risto LAMMINTAUSTA, Mikko UNKILA
-
Publication number: 20170081356Abstract: The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R2, R3, R4, R7 and R8 are as defined in the claims. The invention further relates to their use as inhibitors of 17?-HSD1 and in treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17?-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof.Type: ApplicationFiled: June 25, 2014Publication date: March 23, 2017Applicant: FORENDO PHARMA LTDInventors: Leena HIRVELÄ, Lauri KANGAS, Pasi KOSKIMIES, Risto LAMMINTAUSTA, Mikko UNKILA